Joseph Pantginis

Yigal Nochomovitz

Farzin Haque

Kalpit Patel

Amin Makarem

Ayan Hussein

Kristen Kluska

- Rigel Pharmaceuticals reported strong commercial growth, with **$102 million** achieved in the first half of **2025**, and **Q2 2025** alone showing **76% growth** over **Q2 2024**.  **[1034842_tx_379731_1]**  TAVALISSE grew **52%** and Rezlidia grew **36%** year-over-year.  **[1034842_tx_379731_3]** **[1034842_tx_379731_4]** 
- The company raised its **2025** total revenue guidance to **$270 million to $280 million** (previously **$200 million to $210 million**) and net product sales revenue to **$210 million to $220 million**.  **[1034842_tx_379731_8]**  Rigel was profitable in **2024** and reported **$71 million** in profit for the first six months of **2025**, with a cash position increasing to **$108 million** by the end of **Q2 2025**.  **[1034842_tx_379731_8]** 
- Rigel is advancing its development programs, including R289 for lower-risk myelodysplastic syndromes, which has received Fast Track and Orphan Drug designation and showed promising early data with **three out of ten** highly refractory patients achieving transfusion independence.  **[1034842_tx_379731_5]** **[1034842_tx_379731_6]**  The dose expansion phase for R289 is expected to begin in **September or early October 2025**.  **[1034842_tx_379731_5]**

RIGEL PHARMACEUTICALS (RIGL)